Please assess the completion status of the following clinical trial:

Trial Title: Study of Heart Failure Hospitalizations After Aquapheresis Therapy Compared to Intravenous (IV) Diuretic Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18 years of age or older~2. Male or non-pregnant female patients~3. Admitted to the hospital with a primary diagnosis of acute decompensated heart failure (ADHF)~4. On regularly scheduled oral loop diuretics prior to admission~5. Fluid overload manifested by at least two of the following:~   1. Pitting edema (2+) of the lower extremities~  2. Jugular venous distention \> 8 cm~  3. Pulmonary edema or pleural effusion on chest x-ray~  4. Paroxysmal nocturnal dyspnea or ≥ two- pillow orthopnea~  5. Respiration rate ≥ 20 per minute.~6. Have received ≤ 2 IV loop diuretics doses before randomization~7. Must be able to be enrolled into the trial ≤ 24 hours of their admission to the hospital.~8. Provide written informed consent form as required by the local IRB (Institutional Review Board)~Exclusion Criteria:~1. Acute coronary syndromes~2. Renal insufficiency with a sCr ≥ 3.0 mg/dl or planned renal replacement therapies~3. Systolic blood pressure \< 90 mmHg at time of enrollment~4. Pulmonary Arterial Hypertension not secondary to left heart disease~5. Contraindications to systemic anticoagulation~6. Hematocrit \> 45%~7. Inability to obtain venous access~8. Hemodynamic instability severe enough to require IV positive inotropic agents, IV vasodilators or both~9. Use of iodinated radiocontrast material within the previous 72 hours or planned study requiring IV contrast during the current hospitalization~10. Severe concomitant disease expected to prolong hospitalization~11. Severe concomitant disease expected to cause death in ≤ 90 days~12. Sepsis or ongoing systemic infection~13. Severe uncorrected valvular stenosis~14. Active myocarditis~15. Hypertrophic obstructive cardiomyopathy~16. Constrictive pericarditis or restrictive cardiomyopathy~17. Liver cirrhosis~18. Previous solid organ transplant~19. Requirement for mechanical ventilatory support~20. Presence of a mechanical circulatory support device~21. Unwillingness or inability to complete follow up~22. Active drug or ETOH substance abuse~23. Participating in another interventional clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aquapheresis (AQ) - isolated veno-venous ultrafiltration (Type: EXPERIMENTAL): Excess fluid from the patient is removed by isolated veno-venous ultrafiltration treatment using the Aquadex Flex Flow System
- IV Loop Diuretics (LD) (Type: ACTIVE_COMPARATOR): Excess fluid from the patient is removed by IV (Intravenous) loop diuretic treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).